In glaucoma models, Torin 2 preserves retinal nerve cells

A damaged cell component can become a liability when the cleanup system stops working. In two glaucoma models, researchers from the University of Missouri School of Medicine used Torin 2 to enhance autophagy—the process cells use to remove and recycle damaged material—and reported that it preserved more retinal ganglion cells, the retinal nerves that communicate with the brain.

The team’s focus was the mitochondria, the structures that generate usable energy for cells. Retinal ganglion cells process a heavy flow of visual information, and their mitochondria must keep working under that demand. When damaged mitochondria are not cleared, they can build up, creating cellular stress linked to degeneration, according to lead author Prabhavathi Maddineni.

The result was not just about keeping cells alive. The researchers said Torin 2 also improved retinal ganglion-cell function in both glaucoma models. Their paper, published in Molecular Neurodegeneration, describes the approach as a way to restore impaired autophagy and prevent abnormal mitochondrial accumulation.

So what changes, concretely? The finding suggests a possible treatment route beyond lowering eye pressure: help the retinal cells maintain their own internal quality-control system. That could eventually complement current glaucoma care and aim directly at the nerve-cell loss that causes irreversible vision damage.

The limits are clear. Torin 2 is not approved for human use, and the study does not establish that it is safe or effective in patients. Maddineni’s team now plans to look for more selective, clinically translatable ways to support autophagy and mitochondrial quality control.